Augmedix (OTCMKTS:AUGX – Get Free Report) and Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.
Volatility and Risk
Augmedix has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500. Comparatively, Firefly Neuroscience has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Earnings and Valuation
This table compares Augmedix and Firefly Neuroscience”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Augmedix | $51.58 million | 2.23 | -$24.45 million | ($0.43) | -5.47 |
| Firefly Neuroscience | $1.14 million | 15.20 | -$19.88 million | ($0.63) | -1.76 |
Firefly Neuroscience has lower revenue, but higher earnings than Augmedix. Augmedix is trading at a lower price-to-earnings ratio than Firefly Neuroscience, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Augmedix and Firefly Neuroscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Augmedix | -57.70% | -980.09% | -57.85% |
| Firefly Neuroscience | -506.23% | -106.16% | -80.85% |
Institutional & Insider Ownership
87.1% of Augmedix shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 11.0% of Augmedix shares are owned by company insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings for Augmedix and Firefly Neuroscience, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Augmedix | 0 | 0 | 0 | 0 | 0.00 |
| Firefly Neuroscience | 1 | 0 | 0 | 0 | 1.00 |
About Augmedix
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
About Firefly Neuroscience
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with MarketBeat.com's FREE daily email newsletter.
